SCHEMBL6258964

SCHEMBL6258964

c1ccc(CNc2ccnc(Nc3ccc4cc[nH]c4c3)n2)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 4/20 0.47
KDM4E B2RXH2 1/20 0.45
NPC1 O15118 1/20 0.45
TP53 P04637 1/20 0.45
HPGD P15428 1/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
KCNH2 Q12809 2/20 0.45
EGFR P00533 1/20 0.44
PTK2 Q05397 6/20 0.43
PTK2B Q14289 4/20 0.43
DYRK1A Q13627 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
PLK4 O00444 1/20 0.42
HRH3 Q9Y5N1 1/20 0.41
BTK Q06187 1/20 0.41
IGF1R P08069 1/20 0.41
FGFR1 P11362 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6260423 0.91 EGFR (0.51) SYKKDM4ENPC1TP53HPGD
SCHEMBL6239489 0.84 KDR (0.57) SYKKDM4ENPC1TP53HPGD
SCHEMBL6216051 0.82 AURKA (0.61) SYKKDM4ENPC1TP53HPGD
SCHEMBL6209413 0.82 QPCT (0.45) SYKKDM4ENPC1TP53HPGD
SCHEMBL879564 0.81 EGFR (0.52) SYKEGFRPLK4HRH3BTK
SCHEMBL6211607 0.81 PTK2 (0.64) SYKEGFRPTK2PTK2BIGF1R
SCHEMBL6260019 0.81 PTK2 (0.52) SYKEGFRPTK2PTK2BDYRK1A
SCHEMBL6260739 0.81 EGFR (0.49) SYKNPC1RAB9AEGFRPTK2
SCHEMBL6259622 0.80 PTK2 (0.67) SYKEGFRPTK2PTK2BDYRK1A
SCHEMBL28637798 0.79 PTK2 (0.43) SYKNPC1RAB9AKCNH2PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP claimed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US claimed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO claimed
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US disclosed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220177-A1 Compound for the treatment of abnormal cell growth CCNA1, CCNB1, CCNT1 SYK 4128/4885KDM4E 2081/4885NPC1 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.